,0
symbol,PHAS
price,3.68
beta,0.0
volAvg,223384
mktCap,107981872
lastDiv,0.0
range,2.6-8.49
changes,0.01
companyName,PhaseBio Pharmaceuticals Inc
currency,USD
cik,0001169245
isin,US7172241090
cusip,717224109
exchange,NasdaqGS
exchangeShortName,NASDAQ
industry,Biotechnology
website,https://phasebio.com/
description,"PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 32 full-time employees. The firm is focused on the development and commercialization of therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The Companyâ€™s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor, which the Company is developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. Its product candidate, PB1046, is a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, or PAH. PB1046 utilizes its proprietary elastin-like polypeptide (ELP), technology, which also serves as the engine for its preclinical pipeline. Its ELP biopolymer technology utilizes a mechanism of slow absorption through a reversible phase transition and a prolonged circulatory half-life."
ceo,Mr. Jonathan Mow
sector,Healthcare
country,US
fullTimeEmployees,40
phone,16109816500
address,1 Great Valley Pkwy Ste 30
city,Malvern
state,PENNSYLVANIA
zip,19355
dcfDiff,
dcf,6.14245
image,https://financialmodelingprep.com/image-stock/PHAS.png
ipoDate,2018-10-18
defaultImage,False
